Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said
You may also be interested in...
Pfizer Pipeline Update Highlights 85 New Molecular Entities, 14 New Claims
Pfizer will resubmit the NDA for its next-generation selective estrogen receptor modulator lasofoxifene in December with new data, the drug maker said in a pipeline update released Aug. 6
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.